Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients

BACKGROUND: Erythropoiesis-stimulating agents including epoetin alfa have been a mainstay of anemia management in patients with chronic kidney disease. Although the standard practice has been to administer epoetin alfa to patients on hemodialysis (HD) intravenously (IV), subcutaneous (SQ) epoetin al...

Descripción completa

Detalles Bibliográficos
Autores principales: Prasad, Bhanu, Jafari, Maryam, Toppings, Julie, Gross, Linda, Kappel, Joanne, Au, Flora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273547/
https://www.ncbi.nlm.nih.gov/pubmed/32547774
http://dx.doi.org/10.1177/2054358120927532

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273547/
https://www.ncbi.nlm.nih.gov/pubmed/32547774
http://dx.doi.org/10.1177/2054358120927532

Ejemplares similares